bpc-157 clinical evidence safety human trials review Peptide Therapy for Pain Management and Healing FDA commitee votes 8-6 to

You're not going to be able to do a goddamn thing

IGF-1 LR3 1MG is structurally modified from native IGF-1 through an arginine substitution at position 3 and a 13amino acid extension at the N-terminus

This compound serves as a high-affinity carrier for divalent copper ions, facilitating the study of collagen synthesis, glycosaminoglycan regulation, and the activation of antioxidant enzymes such as superoxide dismutase (SOD)

Timeline: High-dose results won't be available until 2028+, well after standard-dose approval

Therefore, timing with meals is irrelevant as it doesnt face degradation from stomach acid or enzymes

Lack of Clinical Data : The safety and efficacy data supporting tirzepatide use come exclusively from studies using FDA-approved formulations